GENE ONLINE|News &
Opinion
Blog

2022-05-11| Partnerships

NVIDIA & Singular Genomics Team Up to Boost Next-Gen Sequencing Capabilities

by Fujie Tham
Share To

Singular Genomics Systems and NVIDIA are teaming up to validate and optimize the G4 Sequencing Platform with NVIDIA Clara Parabricks for accelerated bioinformatics applications. 

The G4 sequencer is Singular Genomics’ first benchtop sequencing platform, utilizing its exclusive ​​4-color sequencing by synthesis (SBS) chemistry and equipped with NVIDIA RTX A6000 for AI-enabled basecalling. This collaboration will enable Clara Parabricks access for the Singular’s G4 sequencing system, enabling accelerated bioinformatics applications in whole-genome, cancer, RNA sequencing, and targeted gene screening, coupled with Amazon Cloud functionalities.

As demand for sequencing increases, the volume of data generated grows exponentially, algorithms and workflows used for data analysis are known to be the primary bottleneck. NVIDIA’s Clara Parabricks addresses this issue with an accelerated and scalable suite optimized for genomic analysis on graphics processing units (GPUs). This collaboration further extends NVIDIA’s technology to downstream genomics workflow. 

“Time to results is crucial across most NGS applications, and we believe that Clara Parabricks and NVIDIA’s best-in-class GPU architecture combined with the speed and flexibility of the G4 Sequencing Platform is a natural fit,” said George Vacek, NVIDIA Global Director of Genomics Alliances.

Related article: Cancer Cells Build Nano-Highways to Hijack Mitochondria from Immune Cells

 

Singular Genomics’ First Commercial Sequencing Platform

 

Aiming to compete with Illumina in the benchtop sequencer market, the San Diego-based company went public in May 2021 and launched its first commercial sequencer later that year. Singular Genomics has deals to make sample library preparation kits from Twist Bioscience, New England BioLabs, and Dovetail compatible with its platform, integrating established workflows into the G4.

Wasting no time to support its first product, the company later secured a partnership with Broad Institute to integrate the Terra platform developed jointly with Microsoft and Alphabet into G4, further ameliorating its cloud data analysis abilities.

The G4x4, a four-instrument configuration designed to address customers with high sequencing output demands, is scheduled for launch before the end of 2022. The company did not disclose any financial and other terms of the NVIDIA agreement.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
JPM 2024: Generative AI Reshapes Medical Paradigms, Transforming the Past
2024-01-15
R&D
Revolutionary Sequencing Technique for Cancer Signature Detection
2023-07-11
LATEST
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top